Compile Data Set for Download or QSAR
Report error Found 634 Enz. Inhib. hit(s) with Target = 'Capsid protein'
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50248008(CHEBI:473990 | BMS-200475-01 | Baraclude | Entecav...)
Affinity DataEC50:  0.240nMAssay Description:Inhibition of hepatitis B virus capsid assembly infected in human HepG2.215 cells assessed as reduction in viral DNA replication measured on day 7 by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50247812(CHEMBL3742114)
Affinity DataEC50:  1nMAssay Description:Inhibition of hepatitis B virus capsid assembly infected in human HepG2.215 cells assessed as reduction in viral DNA replication measured on day 7 by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50592300(CHEMBL5187151)
Affinity DataEC50:  1.60nMAssay Description:Modulation of capsid assembly in HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replicationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM473068(US10836769, Example 54)
Affinity DataEC50:  1.60nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM473029(US10836769, Example 16)
Affinity DataEC50:  1.80nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM400082(US10328053, Compound 60 | N-(3-chloro-4-fluorophen...)
Affinity DataEC50:  1.80nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM400062(US10328053, Compound 40 | (1aR,6aR)-5-(2-((3,3-dif...)
Affinity DataEC50:  1.90nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM473038(US10836769, Example 25)
Affinity DataEC50:  1.90nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50530984(CHEMBL4077913)
Affinity DataEC50:  2nMAssay Description:Inhibition of capsid in HBV infected in human HepG.2.2.15 cells assessed as reduction of HBV DNA incubated for 5 days by quantitative PCR analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50530997(CHEMBL4587268)
Affinity DataEC50:  2nMAssay Description:Inhibition of capsid in HBV infected in human HepG.2.2.15 cells assessed as reduction of HBV DNA incubated for 5 days by quantitative PCR analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50530997(CHEMBL4587268)
Affinity DataEC50:  2nMAssay Description:Inhibition of capsid in HBV infected in human HepG.2.2.15 cells assessed as reduction of HBV DNA incubated for 5 days by quantitative PCR analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50530984(CHEMBL4077913)
Affinity DataEC50:  2nMAssay Description:Inhibition of capsid in HBV infected in human HepG.2.2.15 cells assessed as reduction of HBV DNA incubated for 5 days by quantitative PCR analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM400064(US10328053, Compound 42 | (1aR,6aR)-5-(2-((3,3-dif...)
Affinity DataEC50:  2.10nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM400061(US10328053, Compound 39 | (1aR,6aR)-N-(3-chloro-4-...)
Affinity DataEC50:  2.10nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM472982(US10836769, Example 3)
Affinity DataEC50:  2.30nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM473031(US10836769, Example 18)
Affinity DataEC50:  2.40nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM472915(US10836769, Example 1)
Affinity DataEC50:  2.5nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM473027(US10836769, Example 14)
Affinity DataEC50:  2.60nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50586546(CHEMBL5091507)
Affinity DataEC50:  2.70nMAssay Description:Modulation of capsid assembly in HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication preincubated for 3 days follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM400111(US10328053, Compound 89 | 7-(2-((3,3-difluoro-1-(1...)
Affinity DataEC50:  2.90nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM473053(US10836769, Example 39)
Affinity DataEC50:  2.90nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50247811(CHEMBL4078766)
Affinity DataEC50:  3nMAssay Description:Inhibition of hepatitis B virus capsid assembly infected in human HepG2.215 cells assessed as reduction in viral DNA replication measured on day 7 by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2020
Entry Details Article
PubMed
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50531001(CHEMBL4446995)
Affinity DataEC50:  3nMAssay Description:Inhibition of capsid in HBV infected in human HepG.2.2.15 cells assessed as reduction of HBV DNA incubated for 5 days by quantitative PCR analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50585292(CHEMBL5072925)
Affinity DataEC50:  3nMAssay Description:Modulation of capsid assembly in HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication by particle gel assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50530983(CHEMBL4577679)
Affinity DataEC50:  3nMAssay Description:Inhibition of capsid in HBV infected in human HepG.2.2.15 cells assessed as reduction of HBV DNA incubated for 5 days by quantitative PCR analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50237769(CHEMBL4064672)
Affinity DataEC50:  3nMAssay Description:Inhibition of capsid in HBV infected in human HepG.2.2.15 cells assessed as reduction of HBV DNA incubated for 5 days by quantitative PCR analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM473069(US10836769, Example 55)
Affinity DataEC50:  3nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50237769(CHEMBL4064672)
Affinity DataEC50:  3nMAssay Description:Inhibition of capsid in HBV infected in human HepG.2.2.15 cells assessed as reduction of HBV DNA incubated for 5 days by quantitative PCR analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50530983(CHEMBL4577679)
Affinity DataEC50:  3nMAssay Description:Inhibition of capsid in HBV infected in human HepG.2.2.15 cells assessed as reduction of HBV DNA incubated for 5 days by quantitative PCR analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM580439(US11491148, Compound C33R* | US11491148, Compound ...)
Affinity DataEC50:  3nMAssay Description:The anti HBV activity was measured using the HepG2.117 cell line, a stable, inducible HBV producing cell line, which replicates HBV in the absence of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50531001(CHEMBL4446995)
Affinity DataEC50:  3nMAssay Description:Inhibition of capsid in HBV infected in human HepG.2.2.15 cells assessed as reduction of HBV DNA incubated for 5 days by quantitative PCR analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM400051(US10328053, Compound 29 | N-(3-chloro-4-fluorophen...)
Affinity DataEC50:  3.10nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM400075(US10328053, Compound 53 | 7-(2-((3,3-difluoro-1-(1...)
Affinity DataEC50:  3.20nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM473063(US10836769, Example 49)
Affinity DataEC50:  3.20nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM400053(US10328053, Compound 31 | 7-(2-((3,3-difluoro-1-(1...)
Affinity DataEC50:  3.20nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50586547(CHEMBL5082468)
Affinity DataEC50:  3.40nMAssay Description:Modulation of capsid assembly in HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication preincubated for 3 days follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM473051(US10836769, Example 37)
Affinity DataEC50:  3.60nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM400121(US10328053, Compound 100 | (1aR,6aR)-5-(2-((3,3-di...)
Affinity DataEC50:  3.70nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM473034(US10836769, Example 21)
Affinity DataEC50:  3.90nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50592294(CHEMBL5188597)
Affinity DataEC50:  4nMAssay Description:Modulation of capsid assembly in HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replicationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50585291(CHEMBL5075092)
Affinity DataEC50:  4nMAssay Description:Modulation of capsid assembly in HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication by particle gel assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50592295(CHEMBL5190770)
Affinity DataEC50:  4nMAssay Description:Modulation of capsid assembly in HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replicationMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50586555(CHEMBL5077493)
Affinity DataEC50:  4nMAssay Description:Modulation of capsid assembly in HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication preincubated for 3 days follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50586559(CHEMBL5093261)
Affinity DataEC50:  4nMAssay Description:Modulation of capsid assembly in HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication preincubated for 3 days follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50586545(CHEMBL5091824)
Affinity DataEC50:  4nMAssay Description:Modulation of capsid assembly in HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA replication preincubated for 3 days follo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM473030(US10836769, Example 17)
Affinity DataEC50:  4.10nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM473019(US10836769, Example 8)
Affinity DataEC50:  4.70nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM472932(US10836769, Example 2)
Affinity DataEC50:  4.80nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/30/2021
Entry Details
US Patent

TargetCapsid protein(HBV-C)
Gilead Sciences

US Patent
LigandPNGBDBM400033(US10328053, Compound 12 | 7-(2-((1-(1,3,4-thiadiaz...)
Affinity DataEC50:  5nMAssay Description:A HepG2 cell line overexpressing the HBV virus attachment receptor sodium-taurocholate cotransporting polypeptide (NTCP) was grown to confluency in D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2021
Entry Details
US Patent

TargetCapsid protein(HBV)
Sunshine Lake Pharma

Curated by ChEMBL
LigandPNGBDBM50531002(CHEMBL4517178)
Affinity DataEC50:  5nMAssay Description:Inhibition of capsid in HBV infected in human HepG.2.2.15 cells assessed as reduction of HBV DNA incubated for 5 days by quantitative PCR analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2021
Entry Details Article
PubMed
Displayed 1 to 50 (of 634 total ) | Next | Last >>
Jump to: